Oxygen Therapy for Cognitive Function: HBOT, Brain Aging, and the Evidence
Explore the clinic directoryIn this article
- The Tel Aviv Protocol: HBOT for Brain Aging
- HBOT for Traumatic Brain Injury
- HBOT for Stroke Recovery
- HBOT for Long COVID and Brain Fog
- Normobaric Oxygen for Cognition
- How Oxygen Affects Brain Health
- Who Might Benefit
- Evidence Quality: An Honest Assessment
- Cost and Practical Considerations
- Frequently asked questions
- The Bottom Line
Hyperbaric oxygen therapy (HBOT) has produced measurable, statistically significant improvements in cognitive function across multiple controlled trials, with the strongest evidence in traumatic brain injury, stroke recovery, and age related cognitive decline. In a 2020 randomized controlled trial, 60 sessions of HBOT improved attention, information processing speed, and executive function in adults over 64, with gains confirmed on brain imaging. The Tel Aviv protocol, in particular, has produced some of the most compelling brain imaging data in the field.
What this article covers
Key Takeaways
- A 2020 randomized controlled trial from Tel Aviv University showed HBOT improved attention, information processing speed, and executive function in healthy adults over 64.
- HBOT for post-concussion syndrome and chronic TBI has shown cognitive improvements in multiple studies, though results are debated.
- Early sham controlled research suggests HBOT may ease long COVID brain fog, but the evidence base is smaller than for TBI or stroke.
- Normobaric oxygen (breathing 100% O2 at normal pressure) has limited evidence for cognitive enhancement.
- The proposed mechanism involves increased cerebral blood flow, neuroplasticity, and stem cell mobilization.
- HBOT is not FDA cleared for cognitive decline, dementia, or long COVID, so these uses are off label and typically paid out of pocket.
The Tel Aviv Protocol: HBOT for Brain Aging
The most widely cited HBOT cognitive study comes from the Sagol Center for Hyperbaric Medicine at Shamir Medical Center, affiliated with Tel Aviv University. Led by Professor Shai Efrati, the team has published a series of studies examining HBOT’s effects on brain function.
In a 2020 randomized controlled trial published in the journal Aging, Efrati and colleagues studied 63 healthy adults aged 64 and older. The HBOT group (n=33) received 60 sessions of 100% oxygen at 2.0 ATA (atmospheres absolute) for 90 minutes each, five days per week for 12 weeks. The control group (n=30) received no intervention during the study period.[1]
Results showed significant improvements in the HBOT group across several cognitive domains:
- Attention: Measured improvement on computerized cognitive assessment
- Information processing speed: Faster response times on standardized tests
- Executive function: Better performance on tasks requiring planning, flexibility, and inhibition
- Global cognitive function: Overall composite score improvement
Brain imaging (perfusion MRI) showed these cognitive improvements correlated with increased cerebral blood flow in specific brain regions, particularly the prefrontal cortex and temporal lobes.
“HBOT can induce significant enhancement in the cognitive performance of healthy aging adults, with improvements in attention, information processing speed, and executive function correlating with increased cerebral blood flow.”
Hadanny et al., Aging, 2020
HBOT for Traumatic Brain Injury
TBI, ranging from mild concussions to severe brain injuries, is one of the most studied applications of HBOT for cognitive impairment. The evidence picture is complex.
Positive Findings
A 2013 study by Boussi-Gross and colleagues treated 56 patients with post-concussion syndrome (1-5 years after mild TBI) and found significant improvements in cognitive function and quality of life after 40 HBOT sessions at 1.5 ATA.[2]
Multiple case series and observational studies have reported cognitive improvements in chronic TBI patients, even years after injury. These typically show gains in memory, attention, and processing speed.[3]
Contested Results
The HOPPS trial (2015), a Department of Defense-funded RCT, compared HBOT at 2.4 ATA to a sham condition (1.3 ATA air) in military personnel with persistent post-concussion symptoms. Both groups improved equally, leading investigators to conclude HBOT was not effective. However, critics noted that the “sham” condition at 1.3 ATA may itself be a therapeutic dose, making it an active treatment rather than a true placebo.[4]
This debate around appropriate sham controls has plagued HBOT research. Any pressurized environment, even with room air, delivers slightly more oxygen to tissues than normal, potentially producing physiological effects.
For readers mapping out options after a brain injury, the traumatic brain injury treatment guide and the traumatic brain injury condition overview cover how HBOT fits alongside other rehabilitation approaches.
HBOT for Stroke Recovery
Efrati’s group also studied HBOT in chronic stroke patients (6-36 months post-stroke). A 2013 crossover trial showed HBOT improved neurological function and quality of life in patients who had plateaued in their recovery. Brain imaging demonstrated increased metabolic activity in stroke-affected regions.[5]
The proposed explanation is that HBOT can reactivate “stunned” neurons in the ischemic penumbra, the area of brain tissue surrounding the stroke core that is damaged but not dead. These neurons may be metabolically dormant due to insufficient oxygen supply.
HBOT for Long COVID and Brain Fog
Cognitive symptoms are among the most common complaints in long COVID, with patients describing brain fog, slowed thinking, and memory lapses that can persist for months after the acute infection clears. Researchers have tested HBOT as a way to address the microvascular and hypoxic changes thought to drive these symptoms.
A sham controlled trial by Zilberman-Itskovich and colleagues, published in Scientific Reports in 2022, reported improvements in global cognitive scores and energy levels among long COVID patients who completed a course of HBOT, compared with those who received a sham protocol. The pattern echoes the Tel Aviv aging and stroke trials: cognitive gains that track with improved brain perfusion rather than with symptom reporting alone.
The evidence here is earlier stage than the TBI and stroke literature, built on a smaller number of trials. Readers researching persistent post-COVID brain fog can review the broader long COVID treatment guide or the dedicated look at HBOT long COVID clinical data.
Normobaric Oxygen for Cognition
Breathing 100% oxygen at normal atmospheric pressure (normobaric hyperoxia) has also been studied for cognitive effects, but the evidence is much thinner.
A handful of laboratory studies have shown that breathing supplemental oxygen can temporarily improve memory performance and reaction times in healthy subjects. The effects appear during oxygen administration and for a short time afterward, but they are modest and transient.[6]
There is no evidence that normobaric oxygen produces lasting cognitive enhancement. The physiological rationale is weaker than for HBOT because normal atmospheric pressure cannot drive oxygen deep into hypoxic tissue the way pressurized delivery can.
How Oxygen Affects Brain Health
The brain consumes roughly 20% of the body’s oxygen despite being only 2% of body weight. It is exquisitely sensitive to oxygen supply. HBOT’s cognitive effects likely involve several mechanisms:
Increased oxygen delivery to hypoxic tissue. Under pressure, oxygen dissolves directly into plasma at much higher concentrations than hemoglobin alone can carry. This oxygen reaches tissues that are poorly perfused due to damaged blood vessels.
Angiogenesis. Repeated HBOT sessions stimulate the growth of new blood vessels. This improved vascular supply persists after treatment ends, providing lasting benefits to previously under-perfused brain regions.
Neuroplasticity. HBOT appears to upregulate brain-derived neurotrophic factor (BDNF) and other growth factors involved in neuronal repair and synaptic remodeling.
Stem cell mobilization. HBOT has been shown to increase circulating stem cell populations, which may contribute to tissue repair processes in the brain.
Anti-inflammatory effects. Chronic neuroinflammation impairs cognitive function. HBOT reduces inflammatory markers and may help resolve chronic inflammatory states in the brain.
Who Might Benefit
| Population | Evidence Strength | Notes |
|---|---|---|
| Chronic TBI / post-concussion | Moderate | Multiple studies show improvement. Sham control debate ongoing. |
| Chronic stroke (6+ months) | Low-moderate | Promising results from Efrati group. Needs replication. |
| Age-related cognitive decline | Low-moderate | One solid RCT. Mechanism is plausible. |
| Long COVID brain fog | Low | One sham controlled trial reported gains. Needs larger, independent replication. |
| Alzheimer’s / dementia | Very low | Preclinical promise. Human evidence is anecdotal. |
| Healthy cognitive enhancement | Very low | No evidence HBOT enhances cognition in healthy young adults. |
Evidence Quality: An Honest Assessment
The HBOT-cognition research is promising but imperfect. Key limitations include:
- Small sample sizes. Most studies have 30-60 participants. Larger trials are needed.
- Sham control problem. Designing a true placebo for HBOT is difficult because any pressurized environment delivers more oxygen.
- Researcher overlap. A disproportionate number of positive studies come from a small group of researchers (primarily the Efrati/Hadanny team in Tel Aviv). Independent replication is essential.
- Publication bias. Negative results are less likely to be published.
The evidence is strong enough to be taken seriously but not strong enough to make definitive claims about cognitive enhancement.
Cost and Practical Considerations
A cognitive HBOT protocol typically involves 40-60 sessions over 8-12 weeks. At $200-400 per session in the US, this represents a $8,000-24,000 commitment. Insurance generally does not cover HBOT for cognitive indications.
Sessions last 60-90 minutes at pressures of 1.5-2.0 ATA. Most protocols require 5 sessions per week, which means a significant time commitment.
Mild HBOT (1.3-1.5 ATA) in portable chambers is marketed as a more accessible option, but the evidence base is built on protocols using 1.5-2.0 ATA in hard-shell chambers. Results from lower-pressure protocols may differ.
Patients researching a provider can start with the national HBOT clinic directory or the hyperbaric oxygen therapy treatment guide, which explains terms like ATA and session counts in more detail. Listing order in the directory reflects how clinics are organized rather than a paid rank, and a verified label there means a clinic completed credential checks rather than paid for placement. The directory itself is free for patients to use, and inclusion in it is not an endorsement of any single clinic.
Frequently asked questions
What is HBOT and how is it used for cognitive function?
Hyperbaric oxygen therapy, or HBOT, is a treatment in which a person breathes 100% oxygen inside a pressurized chamber, usually at 1.5 to 2.0 ATA. For cognitive indications it is used experimentally, mainly in people with traumatic brain injury, stroke, or age related decline, based on trials showing gains in attention, processing speed, and executive function that correlate with improved cerebral blood flow.
Does hyperbaric oxygen therapy help with brain fog?
Early controlled research, including a 2022 sham controlled trial in long COVID patients, found that a course of HBOT was associated with improvements in cognitive scores and energy compared with sham treatment. The evidence is still limited to a small number of trials, so brain fog relief is best treated as an area of active investigation rather than an established HBOT indication.
How many HBOT sessions are needed to see cognitive improvements?
Most trials showing cognitive benefit used 40 to 60 sessions of 60 to 90 minutes each, delivered five days a week over 8 to 12 weeks at 1.5 to 2.0 ATA. Shorter courses have not been well studied for cognitive outcomes, and protocols below 1.5 ATA have a thinner evidence base for brain related benefits.
Is HBOT approved by the FDA for cognitive decline or dementia?
No. The FDA has cleared hyperbaric oxygen therapy for a specific list of conditions such as decompression sickness, carbon monoxide poisoning, and non healing wounds. Cognitive decline, dementia, traumatic brain injury, and stroke recovery are not on that list, so these uses are off label, typically paid out of pocket, and not governed by a single standardized dosing protocol across clinics.
What are the risks of HBOT for cognitive enhancement?
Reported risks include middle ear barotrauma, temporary changes in vision, and, rarely, oxygen toxicity seizures at higher pressures. These risks are generally low at the 1.5 to 2.0 ATA range used in cognitive studies but are not absent, so a screening exam and supervision by trained staff matter regardless of the indication being treated.
The Bottom Line
HBOT shows genuine promise for cognitive improvement, particularly in people with brain injuries, stroke, or age-related decline. The Tel Aviv research provides the strongest signal, showing measurable gains in cognitive performance that correlate with brain imaging changes. But the field needs larger, independently replicated trials before HBOT can be recommended as a standard cognitive therapy. For now, it remains an experimental intervention with a plausible mechanism and encouraging early results. Readers who want the fuller picture of HBOT protocols, risks, and costs across indications can continue with the complete HBOT guide or the deeper dive on HBOT research.
- Hadanny A, Daniel-Kotovsky M, Suzin G, et al. Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial. Aging (Albany NY). 2020;12(13):13740-13761. doi:10.18632/aging.103571
- Boussi-Gross R, Golan H, Fishlev G, et al. Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury – randomized prospective trial. PLoS One. 2013;8(11):e79995. doi:10.1371/journal.pone.0079995
- Harch PG, Andrews SR, Fogarty EF, et al. A phase I study of low-pressure hyperbaric oxygen therapy for blast-induced post-concussion syndrome and post-traumatic stress disorder. J Neurotrauma. 2012;29(1):168-185. doi:10.1089/neu.2011.1895
- Wolf G, Cifu D, Baugh L, et al. The effect of hyperbaric oxygen on symptoms after mild traumatic brain injury. J Neurotrauma. 2012;29(17):2606-2612. doi:10.1089/neu.2012.2549
- Efrati S, Fishlev G, Bechor Y, et al. Hyperbaric oxygen induces late neuroplasticity in post stroke patients – randomized, prospective trial. PLoS One. 2013;8(1):e53716. doi:10.1371/journal.pone.0053716
- Scholey AB, Moss MC, Neave N, Wesnes K. Cognitive performance, hyperoxia, and heart rate following oxygen administration in healthy young adults. Physiol Behav. 1999;67(5):783-789. doi:10.1016/S0031-9384(99)00183-3